| Literature DB >> 29228753 |
Qi Wang1, Yukun He2, Jun Shen3.
Abstract
OBJECTIVE: To determine a superior surgical treatment for anal fistula through a network meta-analysis and to provide the best direction for development in this field.Entities:
Keywords: anal fistula; network meta-analysis; surgical strategy
Year: 2017 PMID: 29228753 PMCID: PMC5716793 DOI: 10.18632/oncotarget.21836
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flow diagram of the study selection process for this meta-analysis
Characteristics of the included trials
| Author | Country | Pub. Year | Study Arms | Intervention | Included Sample Size (LF) | Follow-up Time | Parameter Data |
|---|---|---|---|---|---|---|---|
| A ba-bai [ | China | 2010 | 2 | SL+BP vs. AF | 90 (0) | 5 months | Recurrence; Healing time; Faecal Incontinence |
| Altomare [ | Italy | 2009 | 2 | SP vs. FG | 62 (2) | 12 months | Recurrence; Faecal Incontinence |
| CHALYA [ | Tanzania | 2013 | 2 | Fo+Ms vs. Fe | 162 (0) | 12 weeks | Recurrence; Healing time; Faecal Incontinence |
| Ellis [ | USA | 2006 | 2 | AF vs. AF+FG | 58 (0) | 36 months | Recurrence |
| FILINGERI [ | Italy | 2004 | 2 | Fo vs. Fe | 20 (2) | 6 months | Recurrence; Healing time; Faecal Incontinence |
| Garciaolmo [ | Spain | 2009 | 2 | BP+FG vs. FG | 49 (1) | 12 months | Recurrence; |
| Hammond [ | UK | 2009 | 2 | BP+FG vs.BP | 28 (1) | 18 months | Recurrence; |
| Han [ | China | 2015 | 2 | SL+BP vs. SL | 235 (2) | 6 months | Recurrence; Healing time; Faecal Incontinence |
| He [ | China | 2009 | 2 | SP vs. Fo | 127 (4) | 3 months | Healing time; |
| Ho [ | Singapore | 1998 | 2 | Fo+Ms vs. Fo | 103 (0) | 3 months | Recurrence; Healing time; Faecal Incontinence |
| Ho [ | Singapore | 2001 | 2 | SP vs. Fo | 100 (8) | 300 days | Healing time; Faecal Incontinence |
| Jain [ | India | 2012 | 2 | Fo+Ms vs. Fe | 40 (0) | 12 weeks | Recurrence; Healing time; Faecal Incontinence |
| Koperen [ | Netherlands | 2011 | 2 | AF vs. FP | 60 (0) | 120 days | Recurrence; Faecal Incontinence |
| Madbouly [ | Egypt | 2014 | 2 | SL vs. AF | 70 (0) | 12 months | Recurrence; Faecal Incontinence |
| Mushaya [ | Australia | 2012 | 2 | SL vs. AF | 39 (2) | 36 weeks | Recurrence; Healing time; Faecal Incontinence |
| Ortiz [ | Spain | 2009 | 2 | AF vs. FP | 42 (1) | 12 months | Recurrence |
| Perez [ | Spain | 2003 | 2 | Fo vs. AF | 55 (0) | 12 months | Recurrence; Healing time; Faecal Incontinence |
| Sahakitrungruang [ | Thailand | 2016 | 2 | Fo+Ms vs. Fo | 50 (0) | 12 weeks | Recurrence; Faecal Incontinence |
| Wang [ | China | 2012 | 2 | SP vs. Fo | 60 (0) | 12 months | Recurrence; Healing time; Faecal Incontinence |
| Zheng [ | China | 2015 | 2 | SL+BP vs. SL | 213 (26) | 180 days | Recurrence; |
BP = Biomaterial Plugging; AF = Advancement Flap; SP = Seton Placement; FG = Fibrin Glue; Fo = Fistulotomy; Fe = Fistulectomy; Ms = Marsupialisation; SL = Surgical Ligation; FP = Fistula Plug; LF = Loss to Follow-up;
Figure 2Methodological quality graph and summary of the included studies
(top) Overall and (bottom) study-level risk of bias.
Figure 3Comparison network of the included RCTs
Each line connected 2 hemostatic strategies from the original studies. The number on the line represents the quality of studies comparing every pair of strategies. Study quality was also represented by the widths of the lines for included treatments regarding (A) healing time, (B) fecal incontinence and (C) recurrence.
Figure 4Ranks of different surgical treatments in terms of parameter-based P values
Results of node−splitting models
| Item | Name | Odds Ratio (95% Confidence Interval) | Relative Effect (95% Confidence Interval) | Overall | |
|---|---|---|---|---|---|
| AF, SL | −6.97 (−24.87, 9.82) | −9.02 (−34.57, 14.76) | −7.52 (−15.29, −0.26) | 0.71 | |
| AF, SL+BP | −17.07 (−34.25, 0.61) | −14.95 (−39.71, 10.07) | −16.40 (−23.99, −9.11) | 0.68 | |
| Fe, Fo | 15.42 (1.48, 31.04) | 20.16 (−2.04, 40.20) | 17.75 (9.44, 25.61) | 0.48 | |
| Fe, Fo+Ms | −7.37 (−20.82, 4.44) | −12.11 (−31.46, 5.68) | −9.56 (−17.15, −1.05) | 0.43 | |
| Fo, Fo+Ms | −28.03 (−43.76, −12.77) | −23.16 (−46.40, −2.25) | −27.48 (−34.20, −18.61) | 0.48 | |
| SL, SL+BP | −8.00 (−24.51, 8.24) | −9.83 (−31.89, 13.73) | −8.87 (−16.67, −1.58) | 0.71 | |
| AF, SL | −1.09 (−3.60, 0.89) | −2.71 (−51.19, 32.35) | −1.00 (−3.65, 0.90) | 0.95 | |
| AF, SL+BP | −8.23 (−49.34, 33.77) | −1.13 (−5.13, 2.56) | −0.94 (−5.13, 2.63) | 0.70 | |
| Fe, Fo | 5.62 (−28.91, 52.64) | 22.53 (−25.07, 63.19) | 3.80 (−22.76, 34.34) | 0.68 | |
| Fe, Fo+Ms | −4.02 (−59.60, 35.32) | 9.73 (−29.69, 43.80) | 1.34 (−25.36, 32.06) | 0.59 | |
| Fo, Fo+Ms | −2.25 (−6.15, 0.52) | −16.11 (−75.36, 34.59) | −2.22 (−5.92, 0.53) | 0.60 | |
| SL, SL+BP | 0.09 (−3.12, 3.07) | −16.96 (−54.49, 14.65) | 0.16 (−3.05, 3.20) | 0.36 | |
| AF, SL | −0.06 (−3.64, 3.51) | −21.18 (−81.35, 32.73) | −0.00 (−3.54, 3.58) | 0.49 | |
| AF, SL+BP | −2.36 (−7.43, 2.45) | −34.93 (−109.56, 31.73) | −2.40 (−7.15, 2.33) | 0.39 | |
| Fe, Fo | 24.73 (−49.00, 111.87) | 18.07 (−46.99, 107.94) | −3.13 (−61.29, 79.50) | 0.94 | |
| Fe, Fo+Ms | −12.62 (−95.16, 65.69) | 12.76 (−59.53, 80.71) | −2.88 (−61.76, 79.27) | 0.62 | |
| Fo, Fo+Ms | −0.12 (−5.11, 5.00) | −57.50 (−188.25, 66.19) | −0.15 (−5.18, 4.90) | 0.33 | |
| SL, SL+BP | −26.69 (−116.70, 35.60) | −2.27 (−8.34, 3.71) | −2.41 (−8.20, 3.53) | 0.52 |